CA2760524C - Recombinant virus-like particles encoded by multi-gene vector - Google Patents

Recombinant virus-like particles encoded by multi-gene vector Download PDF

Info

Publication number
CA2760524C
CA2760524C CA2760524A CA2760524A CA2760524C CA 2760524 C CA2760524 C CA 2760524C CA 2760524 A CA2760524 A CA 2760524A CA 2760524 A CA2760524 A CA 2760524A CA 2760524 C CA2760524 C CA 2760524C
Authority
CA
Canada
Prior art keywords
virus
different
epitopes
proteins
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2760524A
Other languages
English (en)
French (fr)
Other versions
CA2760524A1 (en
Inventor
Corinne John
Christian Schaub
Sabine Wellnitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA2760524A1 publication Critical patent/CA2760524A1/en
Application granted granted Critical
Publication of CA2760524C publication Critical patent/CA2760524C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/866—Baculoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2760524A 2009-05-01 2010-04-30 Recombinant virus-like particles encoded by multi-gene vector Expired - Fee Related CA2760524C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09159287 2009-05-01
EP09159287.3 2009-05-01
PCT/EP2010/055943 WO2010125201A1 (en) 2009-05-01 2010-04-30 Recombinant virus-like particles encoded by multi-gene vector

Publications (2)

Publication Number Publication Date
CA2760524A1 CA2760524A1 (en) 2010-11-04
CA2760524C true CA2760524C (en) 2017-09-12

Family

ID=42544386

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2760524A Expired - Fee Related CA2760524C (en) 2009-05-01 2010-04-30 Recombinant virus-like particles encoded by multi-gene vector

Country Status (12)

Country Link
US (3) US20120064115A1 (https=)
EP (2) EP2424980A1 (https=)
JP (2) JP2012525133A (https=)
KR (1) KR20120018783A (https=)
CN (1) CN102414313B (https=)
AU (2) AU2010243489A1 (https=)
CA (1) CA2760524C (https=)
IL (2) IL216005A (https=)
NZ (1) NZ595710A (https=)
SG (2) SG175781A1 (https=)
WO (1) WO2010125201A1 (https=)
ZA (1) ZA201108036B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2424980A1 (en) * 2009-05-01 2012-03-07 Redbiotec AG Recombinant virus-like particles encoded by multi-gene vector
KR102080061B1 (ko) 2011-06-24 2020-02-21 플루젠, 인코퍼레이티드 인플루엔자 바이러스 돌연변이체들 및 그들의 용도들
CA2885145A1 (en) * 2012-10-30 2014-05-08 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
CN103421845B (zh) * 2013-03-01 2015-10-21 湖州市农业科学研究院 重组质粒pFastdual-polh-da26-Asp、家蚕杆状重组病毒及利用该病毒生产L-天冬酰胺酶Ⅱ的方法
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
US20190000940A1 (en) * 2015-07-31 2019-01-03 Voyager Therapeutics, Inc. Compositions and methods for the treatment of aadc deficiency
US9996448B2 (en) * 2016-02-25 2018-06-12 Red Hat Israel Ltd Breakpoint insertion into kernel pages
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN118949021A (zh) * 2016-03-14 2024-11-15 雷德生物科技股份公司 用于治疗hsv的手段和方法
US10417116B2 (en) * 2016-07-28 2019-09-17 International Business Machines Corporation System, method, and apparatus for crowd-sourced gathering of application execution events for automatic application testing and replay
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
AU2017405996B2 (en) * 2017-03-27 2025-03-27 The University Of Queensland Chimeric insect-specific flaviviruses
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
KR20210019996A (ko) 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 조성물 및 방법
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109731100A (zh) * 2019-02-15 2019-05-10 华南农业大学 基于MultiBac杆状病毒表达系统的禽流感疫苗及制备与应用
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
KR102508574B1 (ko) * 2021-01-22 2023-03-10 주식회사 헬스파크 톡소포자충 단백질 및 인플루엔자 바이러스 단백질을 포함하는 바이러스 유사 입자 및 이를 이용한 진단 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
MXPA02012254A (es) * 2000-06-23 2003-04-25 American Cyanamid Co Montaje de particulas quimericas semejantes al virus de influenza y del tipo silvestre.
US20050186575A1 (en) 2001-05-17 2005-08-25 Rottier Petrus J.M. Corona-virus-like particles comprising functionally deleted genomes
CA2447450C (en) * 2001-05-17 2011-12-20 Universiteit Utrecht Corona-virus-like particles comprising functionally deleted genomes
US7556957B2 (en) 2001-05-17 2009-07-07 Stichting Voor De Technische Wetenschappen Coronavirus-like particles comprising functionally deleted genomes
AU2003901876A0 (en) * 2003-04-17 2003-05-08 The Macfarlane Burnet Institute For Medical Research And Public Health Viral vector
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP2133428A1 (en) 2004-03-09 2009-12-16 Eidgenössische Technische Hochschule Zürich New baculovirus vectors for improved protein production
KR101359723B1 (ko) * 2005-10-18 2014-02-05 노바백스, 인코포레이티드 기능성 인플루엔자 바이러스 유사 입자들
EP1783228A1 (en) 2005-11-08 2007-05-09 ETH Zürich Recombinant expression of multiprotein complexes using polygenes
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
EP2044198A4 (en) * 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
US20110008838A1 (en) * 2007-07-19 2011-01-13 Gale Smith Chimeric varicella zoster virus virus-like particles
EP2424980A1 (en) * 2009-05-01 2012-03-07 Redbiotec AG Recombinant virus-like particles encoded by multi-gene vector

Also Published As

Publication number Publication date
CN102414313A (zh) 2012-04-11
KR20120018783A (ko) 2012-03-05
EP2424980A1 (en) 2012-03-07
AU2014203512B2 (en) 2016-07-14
NZ595710A (en) 2013-10-25
CA2760524A1 (en) 2010-11-04
AU2010243489A1 (en) 2011-12-22
SG10201603033QA (en) 2016-05-30
IL216005A0 (en) 2012-01-31
ZA201108036B (en) 2012-08-29
US20150004690A1 (en) 2015-01-01
SG175781A1 (en) 2011-12-29
IL216005A (en) 2015-08-31
US9309536B2 (en) 2016-04-12
AU2014203512A1 (en) 2014-07-17
JP2016104015A (ja) 2016-06-09
CN102414313B (zh) 2014-04-02
JP2012525133A (ja) 2012-10-22
EP2952581A1 (en) 2015-12-09
WO2010125201A1 (en) 2010-11-04
US20120064115A1 (en) 2012-03-15
US20160194662A1 (en) 2016-07-07
IL240043A0 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
CA2760524C (en) Recombinant virus-like particles encoded by multi-gene vector
US20260000747A1 (en) Influenza virus vaccines and uses thereof
KR101153929B1 (ko) 기능성 인플루엔자 바이러스 유사입자
CN102939096B (zh) 用于预防和治疗流感病毒疾病的疫苗
CA2787099A1 (en) Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
CN106460010A (zh) 治疗cmv之手段及方法
AU2011235220A1 (en) Influenza virus vaccines and uses thereof
US20070286873A1 (en) Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
CN104962581B (zh) 一种表达非洲猪瘟病毒p72蛋白的重组病毒疫苗株
EP3265121B1 (en) Marker system, in particular for baculovirus-expressed subunit antigens
EP4153219A1 (en) Recombinant viruses, insect cells and their uses in viral detection and vaccination
Sari‐Ak et al. VLP‐factory™ and addomer©: Self‐assembling Virus‐Like particle (VLP) technologies for multiple protein and peptide epitope display
CN113950334B (zh) 乙型肝炎病毒特异性t细胞应答
CN114213509B (zh) 基于SARS-CoV-2的S蛋白的疫苗及其用途
HK1166347B (en) Recombinant virus-like particles encoded by multi-gene vector
HK1166347A (en) Recombinant virus-like particles encoded by multi-gene vector
Behzadian et al. Baculoviral Co-Expression of HA, NA and M1 Proteins of Highly Pathogenic H5N1 Influenza Virus in Insect Cells.
WO2011099541A1 (ja) 組換えウイルスの製造方法
JP2025509352A (ja) Ｃｏｖｉｄ－１９の予防に使用するための組み換え型ニューカッスル病ウイルスおよび免疫原性組成物
KR20230156945A (ko) 백신 조성물 및 이의 사용 방법
RU2667429C2 (ru) Композиции и способы для одновременного обнаружения hcv антигена/антитела
CN120718119A (zh) 基于结构设计的稳定于融合前构象的rsv-f蛋白突变体

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150129

MKLA Lapsed

Effective date: 20190430